This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Conde, E. Articles by Sanchez-Cespedes, M. Search for Related Content PubMed PubMed Citation Articles by Conde, E. Articles by Sanchez-Cespedes, M.

Molecular Context of the EGFR Mutations: Evidence for the Activation of mTOR/S6K Signaling

Authors' Affiliations: ¹ Lung Cancer Group and ² Tumour Bank, Spanish National Cancer Centre, ³ Pulmonary and ⁴ Pathology Departments, Hospital Universitario 12 de Octubre, Madrid, and ⁵ Thoracic Surgery Department, Hospital Virgen de la Arrixaca, Murcia, Spain

Requests for reprints: Montserrat Sanchez-Cespedes, Molecular Pathology Programme, Spanish National Cancer Centre, Melchor Fernandez Almagro 3, 28029 Madrid, Spain. Phone: 34-9-1224-6954; Fax: 34-9-1224-6923; E-mail: msanchez{at}cnio.es.

Purpose: Activating somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in a small subset of lung adenocarcinomas. These mutations cluster in specific regions and confer sensitivity to inhibitors of the tyrosine kinase activity of EGFR. To further determine the genetic and molecular characteristics of tumors carrying EGFR gene mutations, we investigated the EGFR gene status in lung adenocarcinomas and evaluated its association with specific characteristics of the patients and tumors, such as mutations at KRAS and p53, EGFR and ErbB2 gene amplification, levels of EGFR and HER2 proteins, and levels of downstream effectors of EGFR, such as phospho–extracellular signal-regulated kinase and phospho-S6 proteins.

Experimental Design: The mutational status of EGFR was determined by direct sequencing in 86 primary lung adenocarcinomas and 12 lung cancer cell lines, and was correlated with a number of variables relating to the tumor and patient. A tissue microarray containing 37 lung tumors was constructed to determine, by fluorescence in situ hybridization analysis, the number of copies of EGFR and ErbB2 genes and, by immunohistochemistry, the levels of EGFR, HER2, phospho-ERK, and phospho-S6 proteins.

Results: EGFR gene mutations were identified in 13% of the primary tumors. The type and clustering of the mutations were identical to those previously reported. Amplification of the EGFR occurred in 14% of the tumors and could arise in tumors with EGFR mutations. Interestingly, mTOR activation, as measured indirectly by augmented levels of phospho-S6 protein, was more frequent in tumors with gene alterations in either EGFR or KRAS (P = 0.00005; Fisher's exact test) than in their wild-type counterparts.

Conclusions: Our data agree with the accumulation of EGFR mutations in a subset of patients with lung cancer. Moreover, we report EGFR gene amplification in EGFR-mutant tumors and a positive correlation between EGFR or KRAS alterations and activation of mTOR signaling.

This article has been cited by other articles:

				P. P. Medina, S. D. Castillo, S. Blanco, M. Sanz-Garcia, C. Largo, S. Alvarez, J. Yokota, A. Gonzalez-Neira, J. Benitez, H. C. Clevers, et al. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer Hum. Mol. Genet., April 1, 2009; 18(7): 1343 - 1352. [Abstract] [Full Text] [PDF]

				P. L. Wagner, E. Hyjek, M. F. Vazquez, D. Meherally, Y. F. Liu, P. A. Chadwick, T. Rengifo, G. L. Sica, J. L. Port, P. C. Lee, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 615 - 621. [Abstract] [Full Text] [PDF]

				J. M. McDonald, C. E. Pelloski, A. Ledoux, M. Sun, G. Raso, R. Komaki, I. I. Wistuba, B. N. Bekele, and K. Aldape Elevated Phospho-S6 Expression Is Associated with Metastasis in Adenocarcinoma of the Lung Clin. Cancer Res., December 1, 2008; 14(23): 7832 - 7837. [Abstract] [Full Text] [PDF]

				J. L. Nakamura, E. Garcia, and R. O. Pieper S6K1 Plays a Key Role in Glial Transformation Cancer Res., August 15, 2008; 68(16): 6516 - 6523. [Abstract] [Full Text] [PDF]

				T. Shimamura, D. Li, H. Ji, H. J. Haringsma, E. Liniker, C. L. Borgman, A. M. Lowell, Y. Minami, K. McNamara, S. A. Perera, et al. Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance Cancer Res., July 15, 2008; 68(14): 5827 - 5838. [Abstract] [Full Text] [PDF]

				Y.-C. Wang, S. K. Kulp, D. Wang, C.-C. Yang, A. M. Sargeant, J.-H. Hung, Y. Kashida, M. Yamaguchi, G.-D. Chang, and C.-S. Chen Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors Cancer Res., April 15, 2008; 68(8): 2820 - 2830. [Abstract] [Full Text] [PDF]

				W. Liu, X. Wu, W. Zhang, R. C. Montenegro, D. L. Fackenthal, J. A. Spitz, L. M. Huff, F. Innocenti, S. Das, E. H. Cook, Jr., et al. Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines Clin. Cancer Res., November 15, 2007; 13(22): 6788 - 6795. [Abstract] [Full Text] [PDF]

				M. Mounawar, A. Mukeria, F. Le Calvez, R. J. Hung, H. Renard, A. Cortot, C. Bollart, D. Zaridze, P. Brennan, P. Boffetta, et al. Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History Cancer Res., June 15, 2007; 67(12): 5667 - 5672. [Abstract] [Full Text] [PDF]

				L. Toschi and F. Cappuzzo Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, February 1, 2007; 12(2): 211 - 220. [Abstract] [Full Text] [PDF]

				R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231. [Abstract] [Full Text] [PDF]